Posts

Understanding the Nexus of Aging and the Increase in Cancer Risk

GCC March Blog Image 1 (640x427)

As Americas’ Greatest Generation continue to age studies are revealing that with the increase in the age of the population comes an increase in cancer risk. The nexus of age and cancer is supported by National Cancer Institute (NCI) research. The convergence of an overall aging population and a peak cancer incidence among those aged 65 to 74 will result in a significant rise in the number of people diagnosed with cancer. In addition, as people age the types of treatments and the eligibility and ability for older patients to participate in clinical trials diminishes.

According to the most recent statistical data from NCI’s Surveillance, Epidemiology, and End Results program, the median age of a cancer diagnosis is 66 years. The median age at diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.

Healthcare professionals treating older cancer patients often discover other health conditions that may limit the use of specific therapies. Unless there is sufficient evidence that older patients can benefit from standard dosage of some therapies, clinicians can be reluctant to give older patients potentially beneficial treatments. This practice of less intensive therapy in aging patients is historically understandable; however, a growing field of geriatric oncologists now consider chronological age insufficient evidence for denying aggressive cancer therapy.

The solution to this aging dilemma, like the disease, is complex and we need to better understand how the biological underpinnings of aging affect the onset and trajectory of cancer. Reasons for this increase of cancer with aging can be contributed to the fact that living longer increases our exposure to things that have been shown to be contributing factors in determining cancer risk, such as exposure to sunlight, radiation, environmental toxins and noxious by-products of metabolism that increase with age. “Most aging cells develop genomic changes that make them more susceptible to the carcinogens in the environment,” says oncologist Lodovico Balducci, who studies and treats cancer in the elderly at the Moffitt Cancer Center in Tampa, Fla. In addition, the various immune defenses that keep our tissues healthy begin to break down with age.

Some of the more serious health conditions that are more common in adults over 65 that may impact the response to a cancer diagnosis include; high blood pressure, heart disease, lung disease, diabetes, kidney disease and arthritis. These co-existing conditions must be taken into account when designing cancer treatment protocols for older patients. For those older patients with cancer, knowing how treatments will be affected by these contributing factors is important to understanding how to respond to the process of therapy.

But progress towards better understanding is underway. A joint collaborative effort with the National Institute on Aging (NIA) and the Samuel Waxman Cancer Research Foundation is underway which will promote and support interdisciplinary research projects, sharing of resources, and development of new technologies and approaches to better understand how the physiological changes associated with aging affect cancer development, progression, and response to therapy. NCI is also committing more resources aimed to increase enrollment for older patients in clinical trials.

Cigarette Smoking a Leading Cause of Preventable Death in United States

GCC February Blog Image 1

On the last Sunday in November 2017, television viewers and print media readers experienced a dramatic moment that continues into this year. The three major U.S. tobacco companies were ordered by the Federal Drug Administration (FDA) to issue the first in what will be a series of five “corrective statements” about their products. The corrective statements are the result of a federal racketeering lawsuit brought against the tobacco companies in 1999 by the Department of Justice. These court-ordered statements, which cover five different topic areas, explain in detail and in plain language the reality of the health harms inflicted by tobacco products upon users. Not that the harmful effects of cigarette smoking on a smoker’s health is anything new. Since the 1960’s, smokers and non-smokers alike have been bombarded with packaging warnings, public awareness campaigns and tobacco advertising bans. In case someone missed the multitude of discussions, the new statements should leave little doubt about the dangers of smoking tobacco.

Cigarette smoking is the leading cause of preventable death in the United States, causing nearly 30 percent of cancer deaths across the country. Of the more than 7,000 chemicals in tobacco smoke, at least 250 are known to be harmful, including hydrogen cyanide, carbon monoxide, and ammonia. Among those, at least 69 can cause cancer. While we are all aware that smoking causes cancer, smoking also harms nearly every bodily organ and organ system in the body and diminishes a person’s overall health. Among the cancers caused are: lung, esophagus, larynx, mouth, throat, kidney, bladder, liver, pancreas, stomach, cervix, colon, and rectum, as well as acute myeloid leukemia. Smoking also causes heart disease, stroke, aortic aneurysm, chronic obstructive pulmonary disease (COPD) (chronic bronchitis and emphysema), diabetes, osteoporosis, rheumatoid arthritis, age-related macular degeneration, and cataracts, and worsens asthma symptoms in adults. There is no safe level of smoking. Smoking even just one cigarette per day over a lifetime can cause smoking-related cancers and premature death.

Despite all the good reasons to quit, kicking the smoking habit is extremely difficult. Studies show that most smokers picked up the habit as a teenager. Cigarettes contain various amounts of Nicotine, the highly addictive drug primarily responsible for a person’s addiction to tobacco products, so quitting can be very difficult even for those already diagnosed with cancer. A study by American Cancer Society researchers found that about 1 in 10 cancer survivors still reports smoking about 9 years after a cancer diagnosis. Lead author Lee Westmaas, PhD, American Cancer Society Director of Tobacco Control Research, says, “Doctors and health care providers must continue to ask survivors about their smoking and provide resources, including medications and counseling, to help them quit.”

Cessation has immediate benefits to a smoker. Ex-smokers suffer from fewer illnesses, lower rates of pneumonia and are healthier overall than people who continue to smoke. Regardless of age, smokers can substantially reduce their risk of bad health. Smokers who quit before age 40 reduce their chance of dying prematurely from smoking-related diseases by about 90%, and the reduction for those who quit by age 45-54 is about two-thirds.

The National Cancer Institute (NCI) and other agencies and organizations can help smokers quit. For more information on organizations that can help you quit smoking, contact the NCI Smoking Quitline at 1–877–44U–QUIT (1–877–448–7848) for individualized counseling, printed information, and referrals to other sources.

Cancer Mortality Rates Continue to Decline in The U.S.

GCC Blog Image 2

Continuing a positive trend for the last two decades, cancer death rates declined again last year. According to annual statistics reported from the American Cancer Society, the cancer death rate for men and women combined has fallen 26% from its peak in 1991. This decline translates to nearly 2.4 million deaths averted during this time period.

“Cancer Statistics, 2018,” was published in the American Cancer Society’s journal CA: A Cancer Journal for Clinicians. The information is also available in a companion report, Cancer Facts and Figures 2018, and on a website, the Cancer Statistics Center. Although cancer death rates continue to decline, a total of 1,735,350 new cancer cases and 609,640 deaths from cancer are projected to occur in the US in 2018.

The decline is mostly due to steady reductions in smoking and advances in early detection and treatment. “This new report reiterates where cancer control efforts have worked, particularly the impact of tobacco control,” said Otis W. Brawley, M.D., chief medical officer of the American Cancer Society. “A decline in consumption of cigarettes is credited with being the most important factor in the drop in cancer death rates. Strikingly though, tobacco remains by far the leading cause of cancer deaths today, responsible for nearly 3 in 10 cancer deaths.”

Lung, breast, prostate, and colorectal cancers are leading the way in lower death rates. Lung cancer death rates declined 45% from 1990 to 2015 among men and 19% from 2002 to 2015 among women. Early detection of breast cancer resulted in a 39 percent decline in death rates in women for the same period. Prostate and colorectal cancer experienced a 52 percent reduction between 1970 and 2015, primarily due to increased routine screening.

According to the report, the reduction in death rates is not equal across all ethnic, racial and social economic classes of population. The rates of new cancer occurrence are generally highest among African Americans and lowest for Asian Americans.

Cancer remains the second most common cause of death among children ages 1 to 14 in the U.S. Leukemia accounts for almost a third of all childhood cancers, followed by brain and other nervous system tumors. While child death rates due to cancer have continuously declined since 1975, cancer incidence rates increased in children and adolescents by 0.6% per year for the same period.

The report also reveals that the lifetime probability of being diagnosed with cancer is 39.7% for men and 37.6% for women. The most common cancers to be diagnosed in men are prostate, lung, and colorectal cancers. The most common cancers to be diagnosed in women are breast, lung, and colorectal cancers. Breast cancer accounts for 30% of all new cancer diagnoses in women. Liver cancer incidence continues to increase rapidly in women, but appears to be stabilizing in men.

The good news is particularly rewarding to the professionals at Gettysburg Cancer Center where their understanding of cancer and how to treat it is constantly evolving toward the day when they have a cure. Testing new procedures for identifying and diagnosing certain diseases and conditions, finding ways to prevent certain diseases or conditions before they have a chance to develop, and exploring new methods of supportive care for patients with chronic diseases are at the core of the ongoing clinical trials at the Center.

The Value of a Community-Based Cancer Center

GCC November Blog Image 2

The diagnosis of Cancer most often is accompanied by an intense emotional reaction, denial and a deep sense of dread and fear. The initial reaction is to seek the most information about the disease and the best treatment options available, no matter the cost of time and expense. The travel can impose a significant burden on cancer patients and their families already struggling with a significant life challenge.

In the historically famous but small community of Gettysburg, Pennsylvania, The Gettysburg Cancer Center (GCC) is meeting the challenges of providing expert comprehensive medical oncology, radiation, diagnostic and radiology services to their community in one location, eliminating the need to travel to regional centers.  With access to expert clinicians and staff, GCC is able to offer quality and comprehensive care in one location.

Adams Diagnostic Imaging (ADI) is an integral part of the GCC. An ACR Certified Imaging Center, ADI is a fully accredited facility focused on providing comprehensive diagnostic services. Whether it is MRI, PET-Scan, Stand Alone CT, Nuclear Medicine, Ultra sound or XRAY, the professional staff at ADI has the latest diagnostic tools available to serve their patient’s specific and individualized needs at affordable prices for the insured and those who self-pay. Their Physicians and highly trained technologists are certified through the ARRT with comprehensive experience and knowledge in radiology. The facility provides flexible scheduling to better accommodate patients by offering longer time slots to improve the patients’ recovery experience.

Clinical trials are an important part of the constantly evolving process of bringing new treatments to market to improve patient outcomes. At GCC, clinical trials are conducted after exhaustive research and development in the lab and are offered to patients to treat or prevent the recurrence of the disease. The first site in the United States to enroll a patient in a pivotal oral chemotherapy trial for all patients with advanced malignancies, GCC clinical trials are some of the most advanced in the field of cancer treatment. The clinical research department at Gettysburg Cancer Center is on the cutting edge of cancer clinical trials.

For more than 25 years, Gettysburg Cancer Center has been committed to providing cancer care in a community-based setting, close to home. The Center works with Hershey Medical Center’s Surgical Oncology Department for all solid tumor board conferences and also collaborates with John Hopkins University and NHI for complicated patient diagnoses.

The Gettysburg Cancer Center prides itself on providing individualized treatment, utilizing the best technical approach, and recognizing each individual patient’s psychological, emotional, and spiritual needs during their journey with their illness and healing.

For more information about Gettysburg Cancer Center, visit www.gettysburgcancercenter.com.

October is Breast Cancer Awareness Month Around the World

GCC Content Blog Image 1 (800x533)

Billed as the most common cancer in women, breast cancer is impacting the lives of one in eight women in the United States. The second leading cause of cancer death in women after lung cancer, breast cancer most commonly occurs in women 50 years of age and older. Breast cancer is caused by a genetic mutation in the DNA of breast cancer cells but how or why this damage occurs isn’t fully understood. Some mutations may develop randomly over time, while others are inherited or may be the result of environmental exposures or lifestyle factors. More than 3.5 million women are living in the U.S. with a history of breast cancer.

Early detection remains the most important factor in the successful treatment and survivability of breast cancer. Caught early when known treatments have the best chance of success, breast cancer is survivable. Successful treatments include surgery, chemotherapy, radiation and immunotherapy. “Risk factors include being female, obesity, a lack of physical exercise, drinking alcohol, hormone replacement therapy during menopause, ionizing radiation, early age at first menstruation, having children late or not at all, older age, and family history.” With the clear lack of knowledge for its causes, early detection of the disease remains the cornerstone of breast cancer control.

National Breast Cancer Awareness Month (NBCAM) was founded in 1985 by the American cancer Society and what is now known as AstraZeneca Pharmaceuticals. Held each October, the event is an attempt to increase the awareness of breast cancer and to aid the solicitation of funds for research and treatment of the disease. NBCAM unites cancer organizations around the world in providing information and support for those suffering from the cancer. Breast Cancer Awareness is represented by the display of pink ribbons, first introduced by the Susan G. Komen Foundation at its New York City race for breast cancer survivors in 1991.

The effort by so many to bring worldwide attention to the disease appears to be having a positive impact. A new report from the American Cancer Society finds that death rates from breast cancer in the United States have dropped 39% between 1989 and 2015. The overall declines in breast cancer death rates have been attributed to both improvements in treatment and early detection by mammograms. The American Cancer Society recommends women find breast cancer earlier when treatments are more likely to be effective. While there is a lack or definite agreement on when and how often screening is most effective, The National Comprehensive Cancer Network recommends annual screening beginning at age 40.

The professional team of oncologists and staff at Gettysburg Cancer Center supports the efforts of Breast Cancer Awareness Month in its world-wide goal to provide the latest information, research, treatment options and support for those who suffer from breast cancer.

Targeted Radiation Therapy Effective For Breast Cancer Patients

A new cancer research project funded by the United Kingdom is revealing some very positive results for breast cancer patients. The study (IMPORT LOW trial), led by The Institute of Cancer Research, London and the Cancer Research UK Cambridge Centre indicates that breast “cancer patients who received radiotherapy targeted at the original tumor site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return.” The results which were recently published in The Lancet, an independent, international weekly general medical journal. “This approach could spare many women significant physical discomfort and emotional distress,” says Professor Arnie Purushotham, Cancer Research UK. “One of the challenges when treating early stage breast cancer is trying to minimize the side effects that can have a real impact on a woman’s life, without affecting the chances of curing her.”

The study included more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of coming back. Radiation therapy or radiotherapy uses ionizing radiation as part of cancer treatment to control or kill malignant cells. A common and effective treatment for breast cancer for many decades, large field radiotherapy is relatively painless in its application, but often the treatments produce side effects that range from low, short term to more severe, long term in nature. Depending on the intensity of the radiation, higher doses can cause varying, acute side effects for months or years following treatment. The nature, severity, and longevity of side effects depend on a number of treatment factors and the individual patient.

Precisely targeted radiation therapy can eradicate all evidence of disease in patients with cancer that has spread to only a few sites. Because radiation destroys cells, targeting the treatment to specific cancer cells limits the collateral damage to areas not affected by the cancer, reducing the side effects suffered by the patient.

The IMPROT LOW trial found that women who received partial radiotherapy reported fewer long term changes to the appearance and feel of their breast, than those who had radiotherapy to the whole breast. Dr. Charlotte Coles, Reader in Breast Radiation Oncology at Cambridge University, chief investigator for the trial and first author of the publication, said, “We started this trial because there was evidence that if someone’s cancer returns, it tends to do so close to the site of the original tumor, suggesting that some women receive unnecessary radiation to the whole breast. Now we have evidence to support the use of less, but equally effective, radiotherapy for selected patients.”

The technique, delivered by standard radiotherapy equipment, may lead to increased use of this treatment at cancer centers across the country and around the world. Professor Judith Bliss, scientific lead for the study within the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, said: “We’re delighted that the results of this trial have the potential to lead to a real change in the way selected breast cancer patients are treated.”

Gettysburg Cancer Center is actively working with researchers on clinical trials, providing alternative treatments for its patients. For more information on clinical trials at Gettysburg Cancer Center, click here.

The Importance of Connecting Patients with Clinical Trials in Cancer Research

July Blog 2 Image

Clinical Trials are at the heart of medical research and are critical to finding new paths to prevent, detect and advance new treatment methods and medications for debilitating diseases. Patients with an illness or disease participate in Clinical Trials in order to receive the benefits of the newest treatment options for recovering from their disease and to offer the best opportunity for researchers to find better treatments for others in the future. Treatments may involve new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe and may also investigate other aspects of patient care, such as improving the quality of life for people with chronic illnesses.

Providing information to patients, who have been diagnosed with a serious disease, about the specifics and availability of important Trials that may be of benefit to them is proving to be challenging.  ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants being conducted around the world and currently lists 247,989 studies with locations in all 50 States and in 201 countries. But accessing, understanding and utilizing this important data can be difficult and challenging for the average patient undergoing the emotional and physical experience of a recent diagnosis.

Former FDA commissioner Dr. Robert Califf recently delivered a talk, “Finding the Right Balance in Learning about Therapies”, at a conference in New York City. In his address he said, “Our country is experiencing an unprecedented divergence of health outcomes that mirrors gaps in wealth and education…wealthy, highly educated people are benefiting from information that allows them to lead longer, more functional lives, while others are suffering. The clinical trials enterprise has gone awry,” he said. “It’s become unnecessarily expensive, cumbersome and arcane” In his opinion the system has become so costly and onerous that most of the important questions go unasked. “Doctors are heavily conflicted between patients and the institutions they work for,” says Dr. Robert. “The rosy view that doctors and patients are discussing all options and making the best decisions flies in the face of all evidence.”

The research and pharma industry is attempting to create new pathways to connect patients with the data and, most importantly, help them understand which clinical trial is best for their particular disease. The “Innovation and Clinical Trial Tracking Factbook 2017”, is an Assessment of the Pharmaceutical Pipeline listing the thousands of new drugs currently under trial across the U.S. and around the world. VitalTrax taps into a global database of clinical trials and ultimately organizes the complex web of information into a platform that allows patients, physicians, caregivers, and families to search for relevant trials in relevant locations – in a language they can understand.

Zikria Syed, CEO of VitalTrax says his company is taking an “Open Table” approach to enrolling patients in clinical trials. “We’re making a big bet on the fact that patients would appreciate tools that put the information, and an ability to learn about clinical trials and enroll, in their own hands.”

In smaller communities around the country local oncology providers are shortening the gap of distance and time for patients seeking the benefits of clinical trials. At the Gettysburg Cancer Center (GCC), Clinical Trials are available to patients who want to participate in this important process. The localized opportunity voids the often long drive to large regional healthcare centers for Trial participants and enhances the patients understanding of the technical and practical elements of the process in a personalized but highly qualified environment.

GCC, a leader in Oncology Care across the Central Pennsylvania region since 1989, is actively involved in providing the latest in clinical trials to their patients throughout their community.

The Resulting Dread of Cancer Survival

July Blog 1 Image (2)

One of the most prolific progressions in research and development over the past decade has been the discovery and development of new treatments and drugs for cancer, for good reason. According to National Cancer Institute (NCI) statistics, cancer has a major impact on our society, both in the United States and around the world.  In 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people died from the disease. Nearly 39.6% of men and women will be diagnosed with cancer at some point during their lifetimes. It is rare to find anyone who has not dealt with the dreaded disease personally or had a family member or acquaintance suffer from one type or another of cancer.

To answer the call for action in defeating the disease, researchers, oncologist and drug companies have turned-up the pace of research and discovery. Over the past 5 years, 68 new cancer drugs have been approved for various cancers, many producing significant improvement in outcomes for patients. In just the last ten years, drug developers and regulators have successfully shortened the R&D path for approving new cancer drugs safely and efficiently. The global market for cancer immunotherapies, cancer drugs that enlist the body’s immune system to improve patient survival rates, are expected to grow more than fourfold globally by 2022. The number of new drugs in the cancer pipeline has swelled by 45% over the past decade alone.

With the increased activity and availability of promising new therapies for the masses suffering from cancer, one would expect that a downward trend in costs would be a positive result of the new competitive environment. But increased competition and quicker access to market is not producing the expected. In previous decades, new drugs might cost around $10,000 for a year’s treatment. However, according to one recent study, today’s newly approved cancer drugs can cost a patient a staggering $120,000 to $170,000 per year.

The result of this revolution appears to come at a high cost for patients. In the past decade patients paid just 5% of healthcare provider revenue. Today the shifting responsibility to patients for these costs has risen to 35%, and the trend is expected to continue as employers continue to transfer the high cost of healthcare insurance to their employees, the trend to higher insurance deductibles and rising operating and regulatory costs. The result is that too many Americans are struggling to afford the care. Many healthcare consumers are avoiding or delaying needed care or abandoning treatment because of concerns about their ability to pay.

In a system where the patient first learns of the price of their treatment after it has been rendered, many are shocked at the staggering high price and confused and amazed by a complicated and convoluted system of service codes and the seemingly unending list of often unseen providers.  The euphoria and promise of this revolution of discovery is leading many to dread the unfathomable price of recovery and survival.

Gettysburg Cancer Center takes pride in seeking alternative financial resources that can assist its patients in managing the costs of their cancer treatment. To learn more, please contact: Erin or Kasey by calling 717.334.4033 or visiting the website at http://gettysburgcancercenter.com/patients/patient-assistance/.

Cancer Diagnosis: A Second Opinion Can Often Lead to the Best Treatment Plan

Most of us would not consider making a major modification to our home without consulting a number of professionals or contractors. After all, getting more than one perspective on the scope of work can reveal a clear understanding of the costs, the potential inconveniences of the process, better prepare for the complexities of the work and more clearly define our expectations. Few of us would argue against the benefits of investing the time and patience in getting a second opinion.

Research shows that half of the patients diagnosed with serious illnesses such as cancer, never seek a second opinion before embarking on a series of treatments for a sometimes life threatening disease. The data reflects that only three percent considered a second opinion to be essential before accepting a diagnosis or course of action. Considering complexities of cancer and the importance of selecting the right course of action for each specific type, it is not just a good idea to initiate a second opinion, it is imperative to understanding all your options and establishing confidence in your final decision. Such important health decisions should be made only after you have learned all you can about your diagnosis, prognosis, available and treatment options.

Several reasons why so many fail to seek a second opinion can be easily explained. A cancer diagnosis is scary; and many patients feel a need to act immediately on a course of treatment to have the best chance of survival. But while in some cases taking immediate action is imperative, most cancer patients have time to learn all there is about their disease before setting out on the treatment journey. Others feel a sense of unquestioned confidence in their personal physician’s ability to diagnose and treat their condition. They often feel that questioning their results could be seen as an insult to their doctor.

Medicine is not an exact science. Even new advancements in treatment options, even the most dedicated and conscientious of practitioners cannot be expected to have the latest science at their fingertips. Many doctors are not only very comfortable with their patients seeking a second opinion, most routinely recommend the action. The results of  “a 2006 study found that when breast cancer patients came to a specialty center for a second opinion, recommendations for surgery changed for more than half, a result of different interpretations and readings of mammograms and biopsy results.”

After Greg Walde received an initial oncology evaluation and treatment at a local oncology center in Gettysburg, Pennsylvania he was told, that due to the advanced stage of his disease, he had little time to live. He was informed that there simply were no effective treatment options for his advanced stage of cancer. The disease, he was informed, had just progressed too far. “At that point,” Greg says, “I went home, very down about things”. After several weeks of distress and depression over his situation he decided to seek another opinion at The Gettysburg Cancer Center just down the street from where he had previously received the bad news. In Greg’s case the value of a second opinion included new treatment options and more time at living his life.

When faced with a cancer diagnosis it becomes critical to find the right oncology center with the experience and dedication to provide the latest and most appropriate medical treatment and support available to fight the battle. At his Gettysburg Cancer Center in Gettysburg, PA, Dr. Satish Shah, Medical Oncologist/Hematologist says, “We understand that every person is unique. Our team is dedicated to providing the latest approaches to treatment in a caring environment for patients and their families to insure the best possible outcome for their cancer treatment.”

For more information on the Gettysburg Cancer Center, visit www.gettysburgcancercenter.com.

The Value of a Second Opinion Provides Alternative Treatment to a Cancer Patient

When faced with a cancer diagnosis, it becomes critical to find the right oncology center that will provide the appropriate medical treatment and emotion support to fight the battle. One Gettysburg resident, when faced with a stage-4 cancer diagnosis, found the right support at Gettysburg Cancer Center (GCC), a growing comprehensive cancer center.

Greg Wale received an initial oncology evaluation and treatment at another local oncology center in Gettysburg, Pennsylvania. The diagnosis showed that cancerous tumors had grown to 4 and 5 inches in diameter and had migrated to the liver, bone, thyroid glands and colon. Greg was just 57 year’s old and was told by oncologists that he had little time to live. There simply were no treatment options for his advanced stage of cancer. The disease, he was informed, had just progressed too far.

“At that point,” Greg says, “I went home, very down about things”. After several weeks of distress and depression over the state of his situation, he drew upon his faith and was “spiritually lead” to the Gettysburg Cancer Center (GCC), just down the block from where he had previously received the bad news. It was here that the centers principle oncologist, Dr. Shah, sat down with Greg to review his case. “I felt very comfortable here where there was a lot of very concerned people with caring hearts,” recounts Greg.

He immediately felt the staff at GCC wanted to help and he sensed that things were going to be different in this place where everyone seemed like family. Dr. Shah and his expert team designed a plan to attack his disease and provide as much time as possible for Greg’s future. With no guarantees, the team embarked upon an individualized course of treatment. After a couple of months, new tests revealed that the progression of the disease appeared to be slowing. According to Greg, “None of us knows how much time we have but it looks like I’m going to have more of it than what was told to me when I was first diagnosed thanks to Dr. Shah and this facility.”

For more than 25 years, Gettysburg Cancer Center has been committed to providing cancer care in a community-based setting close to home. The all-encompassing oncology and hematology programs provide a complete range of diagnosis and treatment. “Here at Gettysburg Cancer Center we understand that each patient and their disease are unique, requiring different approaches to insure the best possible outcome for each patient. Our family of caring and educated staff strives to provide insightful, compassionate care to all of our patients.” says Dr. Shah.

In this case, the value of a second opinion meant a new treatment option and more time for this cancer patient. To view the full patient testimonial: https://www.youtube.com/watch?v=448eg4F_SEg&feature=youtu.be.